The Journal of Pain
Volume 10, Issue 2 , Pages 191-200, February 2009

Diclofenac Potassium Attenuates Dysmenorrhea and Restores Exercise Performance in Women With Primary Dysmenorrhea

  • Ingrid Chantler

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ingrid Chantler, Brain Function Research Group, School of Physiology, University of Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa
  • ,
  • Duncan Mitchell
  • ,
  • Andrea Fuller

Brain Function Research Group, School of Physiology, University of Witwatersrand, Parktown, Johannesburg, South Africa

Received 29 April 2008; received in revised form 15 August 2008; accepted 26 August 2008. published online 28 November 2008.

Abstract 

We assessed the efficacy of diclofenac potassium, a nonsteroidal anti-inflammatory drug, in alleviating menstrual pain and restoring exercise performance to that measured in the late-follicular phase of the menstrual cycle. Twelve healthy young women with a history of primary dysmenorrhea completed, in a random order, laboratory exercise-testing sessions when they were in the late-follicular (no menstruation, no pain) phase of the menstrual cycle and when they were experiencing dysmenorrhea and receiving, in a double-blinded fashion, either 100 mg of diclofenac potassium or placebo. We assessed the women's leg strength (1-repetition maximum test), aerobic capacity (treadmill walking test), and ability to perform a functional test (task-specific test). Compared with placebo, diclofenac potassium significantly decreased dysmenorrhea on the day of administration (Visual Analog Scale, P < .001 at all times). When receiving placebo for menstrual pain, the women's performance in the tests was decreased significantly, compared with when they were receiving diclofenac potassium for menstrual pain (P < .05) and compared with when they were in the late-follicular phase of the menstrual cycle (P < .05 for treadmill test, P < .01 for task-specific test and 1-repetition maximum test). Administration of diclofenac potassium for menstrual pain restored exercise performance to a level not different from that achieved in the late-follicular phase of the cycle.

Perspective

In women with primary dysmenorrhea, menstrual pain, if untreated, decreases laboratory-assessed exercise performance. A recommended daily dose of a readily available nonsteroidal anti-inflammatory drug, diclofenac potassium, is effective in relieving menstrual pain and restoring physical performance to levels achieved when the women were in the late-follicular (no menstruation, no pain) phase of the menstrual cycle.

Key words: Menstrual pain, nonsteroidal anti-inflammatory drugs, physical performance

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a Faculty Research Committee Individual Grant (University of Witwatersrand) and by the National Research Foundation, South Africa.

 None of the authors has a financial interest in the research, and no funding was received from any pharmaceutical companies.

PII: S1526-5900(08)00733-5

doi:10.1016/j.jpain.2008.08.006

The Journal of Pain
Volume 10, Issue 2 , Pages 191-200, February 2009